Larimar Therapeutics, Inc. (LRMR) Misses Q1 EPS by 3c

Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q1 EPS of ($0.27), $0.03 worse than the analyst estimate of ($0.24).

For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Deutsche Bank monitors UK auto sales as Chinese exports grow
• Bernstein remains bullish on SpaceX but sees challenges in telecom ambitions